LEXX
Lexaria Bioscience Corp.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.61
P/S
39.26
EV/EBITDA
-1.52
DCF Value
$-1.62
FCF Yield
-42.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.9%
Operating Margin
-2021.0%
Net Margin
-2067.7%
ROE
-209.6%
ROA
-178.4%
ROIC
-228.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.6M | $-0.07 |
| Q4 2025 | $174.0K | $-2.7M | $-0.14 |
| FY 2025 | $705.9K | $-11.9M | $-0.66 |
| Q3 2025 | $174.0K | $-3.8M | $-0.21 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$1.50
Target (Median)
$1.50
Target Range
$1.50 - $1.50
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
0.48
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.